D Marc Rosen
Overview
Explore the profile of D Marc Rosen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sena L, Kumar R, Sanin D, Thompson E, Rosen D, Dalrymple S, et al.
J Clin Invest
. 2022 Oct;
132(23).
PMID: 36194476
Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological...
2.
Cravero K, Pantone M, Shin D, Bergman R, Cochran R, Chu D, et al.
Oncotarget
. 2022 Feb;
13:373-386.
PMID: 35186194
Activating variants in the PEST region of have been associated with aggressive phenotypes in human cancers, including triple-negative breast cancer (TNBC). Previous studies suggested that PEST domain variants in TNBC...
3.
Godet I, Mamo M, Thurnheer A, Rosen D, Gilkes D
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771673
Hypoxia occurs in 90% of solid tumors and is associated with treatment failure, relapse, and mortality. HIF-1α signaling promotes resistance to chemotherapy in cancer cell lines and murine models via...
4.
Karthikeyan S, Waters I, Dennison L, Chu D, Donaldson J, Shin D, et al.
J Clin Invest
. 2021 Feb;
131(6).
PMID: 33529175
Intratumor heterogeneity is an important mediator of poor outcomes in many cancers, including breast cancer. Genetic subclones frequently contribute to this heterogeneity; however, their growth dynamics and interactions remain poorly...
5.
Rogers O, Antony L, Levy O, Joshi N, Simons B, Dalrymple S, et al.
Mol Cancer Ther
. 2020 Sep;
19(11):2353-2362.
PMID: 32943549
PRX302 is a highly potent, mutant bacterial pore-forming biologic protoxin engineered for selective activation by PSA, a serine protease expressed by benign and malignant prostate epithelial cells. Although being developed...
6.
Button B, Croessmann S, Chu D, Rosen D, Zabransky D, Dalton W, et al.
Breast Cancer Res Treat
. 2018 Dec;
174(2):401-412.
PMID: 30560461
Purpose: Estrogen receptor-alpha (ER) is a therapeutic target of ER-positive (ER+) breast cancers. Although ER signaling is complex, many mediators of this pathway have been identified. Specifically, phosphorylation of ER...
7.
Rogers O, Anthony L, Rosen D, Brennen W, Denmeade S
Oncotarget
. 2018 Jun;
9(32):22436-22450.
PMID: 29854290
Prostate cancer is the most diagnosed malignancy and the second leading cause of cancer-related death in American men. While localized therapy is highly curative, treatments for metastatic prostate cancer are...
8.
Gustin J, Miller J, Farag M, Rosen D, Thomas M, Scharpf R, et al.
Oncotarget
. 2017 Dec;
8(61):103415-103427.
PMID: 29262572
The transcription factor is one of the most frequently mutated genes in breast cancer. Heterozygous mutations, mostly frameshifts, are seen in 15% of estrogen receptor positive breast cancers, the subtype...
9.
Croessmann S, Wong H, Zabransky D, Chu D, Rosen D, Cidado J, et al.
Breast Cancer Res Treat
. 2017 Feb;
162(3):451-464.
PMID: 28190247
Background/purpose: The combined contributions of oncogenes and tumor suppressor genes toward carcinogenesis remain poorly understood. Elucidation of cancer gene cooperativity can provide new insights leading to more effective use of...
10.
Schweizer M, Wang H, Luber B, Nadal R, Spitz A, Rosen D, et al.
Prostate
. 2016 Jun;
76(13):1218-26.
PMID: 27338150
Background: We have previously documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e., Bipolar Androgen Therapy; BAT). Because, an adaptive increase in...